Purpose: To assess the proximal humerus intraosseous (PHIO) catheter placement as a preferred method for venous access over conventional methods, including peripheral intravenous (PIV) and central venous catheters (CVCs), during emergency room resuscitation. Methods: In phase 1, conventional methods for venous access (PIV and CVC) were assessed for all patients presenting to the emergency department resuscitation bay. Outcome measures in both phases were speed, immediate complications, and pain. CVC placement was performed when PIV access was deemed impossible or when rapid volume resuscitation was needed. In phase 2, resuscitations requiring venous access or complicated by failed PIV access attempts underwent PHIO catheter placement. Results: Sixty-two patients received either PIV (57) or CVC (5) catheterization, and 29 patients received 30 PHIO catheters. PHIO catheter placement was significantly faster than conventional methods (1.5 [SD 1.1] versus 3.6 minutes [SD 3.7; p Ͻ 0.001 for PIV, and 15.6 minutes [SD 6.7; p Ͻ 0.0056] for CVC). No major complications were identified in either phase. Minor complications for PIV access included extravasation and placement failure. Minor complications for CVC placement included inability to thread the guidewire. Minor complications with PHIO catheter placement included placement failure, poor flow, and catheter dislodgement. Pain scores associated with PHIO insertion and infusion were higher than those associated with PIV and CVC catheter placement. Conclusion: PHIO catheter placement is significantly faster than PIV and CVC placement with increased minor complication profile and perceived pain. PHIO venous access is absolutely life saving when PIV or CVC placement is difficult or impossible. In recent years, the IO route has become increasingly popular for emergent vascular access in pediatric patients, 2 largely replacing the endotracheal route for medication administration when peripheral intravenous (PIV) access is not available. [3] [4] [5] [6] [7] [8] The use of IO catheters in adults has been largely restricted to the prehospital setting in the civilian world, 9,10 although IO is also gaining popularity among military providers. 11, 12 Previous studies have shown that the IO catheterization is a rapid and easy method for obtaining emergent vascular access, regardless of intravascular volume status. [13] [14] [15] Importantly, most medications may be safely administered via the IO route, and blood taken from IO catheters may be used for most laboratory studies. 16 -19 Flow rates differ between IO sites, however, with the highest rates associated with the proximal humerus in animal studies. 20 Contrast injection through the proximal humeral IO catheter under fluoroscopy shows almost immediate flow into the central circulation. 21 We hypothesized that proximal humerus intraosseous (PHIO) catheterization would be faster and easier than conventional venous access methods for the emergent resuscitation of critically ill or injured patients.
I ntraosseous (IO) cannulation for the infusion of fluids and medications was first described by Drinker et al. 1 
in 1922.
In recent years, the IO route has become increasingly popular for emergent vascular access in pediatric patients, 2 largely replacing the endotracheal route for medication administration when peripheral intravenous (PIV) access is not available. [3] [4] [5] [6] [7] [8] The use of IO catheters in adults has been largely restricted to the prehospital setting in the civilian world, 9, 10 although IO is also gaining popularity among military providers. 11, 12 Previous studies have shown that the IO catheterization is a rapid and easy method for obtaining emergent vascular access, regardless of intravascular volume status. [13] [14] [15] Importantly, most medications may be safely administered via the IO route, and blood taken from IO catheters may be used for most laboratory studies. 16 -19 Flow rates differ between IO sites, however, with the highest rates associated with the proximal humerus in animal studies. 20 Contrast injection through the proximal humeral IO catheter under fluoroscopy shows almost immediate flow into the central circulation. 21 We hypothesized that proximal humerus intraosseous (PHIO) catheterization would be faster and easier than conventional venous access methods for the emergent resuscitation of critically ill or injured patients.
METHODS
This prospective cohort study was conducted at a single major urban level I trauma center, with an annual emergency department (ED) volume of approximately 92,000 patients and an admission rate of 21%, including 10% intensive care unit admissions. The research team included one attending physician and one resident physician from the Department of Emergency Medicine and one attending physician from the Department of Surgery. Approval from the institutional review board (IRB) was obtained before initiation of the study. Consent for catheter placement was waived by the IRB, which deemed the various methods of venous access to be provider preference because all three were consistent with standard of care, with implied consent due to the emergent nature of resuscitation. All venous access was obtained by either an attending or resident physician or a resuscitation nurse under direct attending physician supervision. All healthcare providers involved in the study underwent educational training in-services and standardized testing on IO catheter placement, management, and removal before placing the IO catheters.
To compare the speed and utility of PHIO infusion with conventional venous access methods, PIV, and central venous catheter (CVC), the study was conducted in two phases. Only patients who required venous access and arrived at the resuscitation bay without adequate preexisting venous access (two PIVs or one CVC) were included in either phase of the study.
During phase 1 (mid-February to mid-April 2008), a series of consecutive trauma (room 1) and medical (room 2) resuscitations was observed, and data were collected on a predetermined set of variables including time to catheter placement (first PIV or CVC) with good flow, perceived pain from insertion, complications of catheterization before leaving the ED, presenting complaint, initial vital signs, comorbidities, resuscitation medications administered, and disposition. This data were collected on an IRB-approved standardized data collection form by scribe resuscitation nurses at the time of emergency resuscitation. Measurement of the time to catheter placement with good flow began at the moment when the skin was sterilized before catheter insertion and ended when the flow of intravenous fluids was subjectively deemed to be adequate for resuscitative purposes. In those cases in which the first PIV resulted in extravasation (i.e., a "blown vein"), end time was recorded as the moment in which a subsequent attempt resulted in satisfactory flow of intravenous fluids. In those cases in which multiple PIV attempts failed or PIV was otherwise deemed inappropriate and CVC catheter placement was attempted, beginning time was recorded as the time that the first access intervention (PIV or CVC) was attempted, and ending time was called when the CVC line was in place and adequately secured. All times were rounded up to the nearest minute. Visual Analog Scale (VAS) pain scores were only obtained from patients with a Glasgow Coma Scale (GCS) score of 15.
During phase 2 of the study (mid-June to mid-August 2008), a series of consecutive patients requiring new vascular access during emergent resuscitation in rooms 1 or 2 underwent PHIO catheter placement with either the Vidacare Corporation (San Antonio, TX) EZ-IO AD 15-gauge 25-mm stainless steel needle set or the Vidacare OnControl 15-gauge 68-mm stainless steel needle set. The 68-mm needle set was used in those cases in which the 25-mm needle set was deemed too short for adequate placement. Patients were deemed to require new vascular access if they did not have two functioning PIVs or one CVC in place before arrival in the resuscitation bay. Contraindications to PHIO placement on a given side included ipsilateral humeral fracture, inability to identify anatomic landmarks, previous ipsilateral PHIO catheter placement in the last 24 hours, injury or infection at the insertion site, and provider preference. Providers were instructed to evaluate for PHIO placement on the contralateral side in the event of contraindications for placement on the first side considered. All patients receiving a PHIO catheter received a standard dose of 2 mL to 5 mL (40 to 100 mg) of 2% Lidocaine prepared for IV injection through the PHIO catheter for intraosseous local anesthesia before infusion of fluids or medication, unless the patient had a stated or previously documented allergy to Lidocaine. Data similar to that collected during phase 1 were collected on all PHIO patients and recorded by the scribe nurse on an IRB-approved standardized data collection form. Body mass index (BMI) was also recorded for all patients undergoing PHIO catheterization. Measurement of time to good flow began when the skin was sterilized and ended after successful placement of a PHIO placement, when satisfactory flow of intravenous fluids was observed. In those cases in which good flow was not obtained, the time to catheter insertion placement was recorded, and lack of good flow was recorded as a complication of the procedure. In both phases, complications of line placement during the time that the patient remained in the ED were recorded. All PHIO catheters were placed in one of two ED resuscitation bays, and all PHIO catheters were removed before the patient leaving the ED unless alternate venous access could not be obtained before hospital admission. Regardless of alternate venous access availability, all PHIO catheters were removed within 24 hours of catheter placement.
Patients were monitored for PHIO catheter complications for the duration of their hospitalization, and all PHIO catheter removals were performed by trained study personnel. After PHIO catheter removal, the insertion site was covered with a single band-aid. No pressure dressings or gauze pads were applied to the insertion site at any time after removal. Nurses caring for those patients admitted to the hospital with PHIO catheters in place received a brief in-service from study personnel at the time of the patient's arrival to the floor or intensive care unit. Healthcare providers were instructed that any medication that could be safely infused through a PIV could be infused through the PHIO catheter, and no medication or fluids requiring central venous access (e.g., hypertonic saline) were permitted to be infused through the PHIO catheter. The administration of intravenous dye for computed tomography or other contrast studies through the PHIO was not permitted due to institutional radiology protocols. Patients and healthcare providers were instructed not to move the arm in which the PHIO was placed, although no sling or other tethering device was applied to the arm for immobilization. The only exception to this was in those cases in which the patients required restraints for behavioral or other indications unrelated to the study.
RESULTS
A total of 62 patients (57 PIV and 5 CVC) were in enrolled in phase 1 of the study and four (80%) of the five CVC placements were performed after multiple unsuccessful attempts at PIV catheter placement. One CVC line placement was performed as the first vascular attempt for a patient who was deemed on presentation to have a poor peripheral venous access by the attending physician. Mean time to catheter placement with good flow was 3.6 minutes (SD ϭ 3.7; range, 1-16) in the PIV group and 15.6 minutes (SD ϭ 6.7; range, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] in the CVC group. Successful catheter placement in the PIV group required an average of 1.5 attempts (SD ϭ 1.2; range, 1-8) due to catheter infiltration (i.e., "blown vein") or catheter dislodgement. In the CVC group, an average of 2.4 PIV attempts failed before the first attempt at CVC placement. Once the decision to place a CVC was made, successful placement occurred on the first needle stick attempt in four of the five patients, with one failed attempt due to inability to thread the guide wire in one patient. VAS pain scores averaged 0.9 (SD ϭ 1.4; range, 0 -5; n ϭ 42) with PIV insertion and 1.0 (SD ϭ 1.7; range 0 -3; n ϭ 3) with CVC insertion in patients with a GCS score of 15. All PIV placements were performed by nurse providers, and all CVC placements were performed by attending or resident physician providers. CVC catheters were placed in the subclavian vein in three cases, the femoral vein in one case, and the internal jugular vein in one case. No pneumothoraces or major complications were noted in the CVC group. The only minor complication noted in the CVC group was inability to thread the guide wire in the femoral attempt.
Twenty-nine patients received PHIO catheter placement in phase 2, including one patient who received PHIO placement in the same arm with two subsequent resuscitations 2 weeks apart. Comparative data for phases 1 and 2 venous access methods are recorded in Table 1 . Mean time to access with good flow in the PHIO group was 1.5 minutes (SD ϭ 1.1; range, 1-6; n ϭ 30), significantly faster than that with PIV (p Ͻ 0.001) or CVC (p ϭ 0.0056) placement. VAS pain scores were higher in the PHIO group with a mean pain from insertion of 4.5 (SD ϭ 4.2; range 0 -10; n ϭ 15) and a mean pain from infusion of fluids or medication after Lidocaine administration of 3.8 (SD ϭ 4.1; range 0 -10; n ϭ 12). Fifteen (50%) PHIO placements were made on patients with GCS Ͻ15, and infusion of fluids or medication was not attempted in three (10%) cases due to poor flow. PHIO catheters remained in place for an average of 4.6 hours (SD ϭ 5.7; range, 0.17-21; n ϭ 30) before planned removal or inadvertent dislodgement. No major complications were noted in the PHIO group. Minor complications with PHIO placement included a failed attempt to place the catheter in 2 (6.7%) cases, inability to flush in 3 (10%) cases, slow flow in 1 (3.3%) case, and catheter dislodgement in 11 (36.7%) cases. Ten (90.9%) of the 11 catheter dislodgements occurred with the 25-mm needle set. The average time from catheter placement to dislodgement with the 25-mm needle set was 6.9 hours (SD ϭ 7.3; range 0.17-21; n ϭ 10), and it was 2 hours in one case of 68-mm needle set dislodgement. The average BMI of patients who underwent successful PHIO placement was 24.0 kg/m 2 (SD ϭ 4.2; range, 19.0 -33.0; n ϭ 20) for the 25-mm needle set versus 34.4 kg/m 2 (SD ϭ 3.2; range, 31.1-38.6; n ϭ 5) with the 68-mm needle set.
Demographics and comorbidities were similar between study groups and are recorded in Table 2 . Most patients were African American (79.0% in phase 1 and 93.1% in phase 2) and had multiple comorbidities, including end-stage renal disease, diabetes mellitus, and past or current intravenous drug use (IVDA). No significant difference was seen in the rate of hospital admission (72.6% in phase 1 vs. 70.0% in phase 2; p ϭ 0.800). Two patients (3.2% of patients in phase 1 and 6.7% in phase 2) died during resuscitation in each group.
DISCUSSION
The intraosseous approach has been recommended for emergency venous access when conventional methods fail or require prolonged attempts. 3, 4, 13 Although most studies to date have focused on the proximal tibial insertion site, 11,21 the proximal humerus offers a readily available location for IO catheter placement with rapid access to the central circulation. 20 Our objective was to evaluate the PHIO insertion site for speed of insertion, immediate complication profile, and overall efficacy. We hypothesized that PHIO placement was faster than CVC or PIV insertion, with fewer complications than CVC placement. Although the present study did not have sufficient power to adequately assess for safety of PHIO catheter placement relative to CVC or PIV catheter placement, our initial experience with the PHIO catheter has provided us with several important clinical insights into both the ease and efficacy of its use. To the best of our knowledge, this study represents the largest published clinical trial involving the PHIO insertion site in adults to date, although we would like to acknowledge recent experiences that have been published since the inception of our study. 11, 22 Our results conclusively demonstrate that PHIO catheterization is a quick and easy alternative for venous access in the resuscitation of critically ill patients. The greater tubercle of the humerus offers a large target that, even in obese patients, is easy to hit. In fact, it is difficult to miss. Although all times were rounded up to the nearest minute, venous access was generally obtained in less than 5 seconds. Additional time was required before administration of medication or fluids for slow infusion of 40 mg to 100 mg (2-5 mL) of 2% Lidocaine into the medullary space (more than 10 -20 seconds), followed by a rapid 10 mL flush of normal saline, as well as preparation of a pressure bag for IV fluid infusion. We found that this initial rapid saline flush is very helpful in clearing the medullary space to facilitate subsequent good flow of fluids through the catheter. Despite these additional time requirements, the time from site selection to good flow of IV fluids was still less than that for PIV or CVC insertion. In regards to CVC line placement, it should be emphasized that the time to successful CVC line placement included all previous attempts at intravenous access, and that in four of the five cases an average of three PIV attempts were made before CVC placement was deemed necessary by the attending physician. In only one case was CVC access the first provider preference for purposes of resuscitation. The decision to record time to successful CVC placement in this manner was made before the study's initiation, because the measured outcome in this study was time to the establishment of satisfactory IV access with good flow. Consequently, this data should not be taken out of context or interpreted as the time needed for CVC placement alone. Only five CVC placements were observed in this study, which further limits our ability to provide an accurate assessment of the time needed to perform CVC placement. The time needed to establish reliable CVC access may be highly variable between institutions and should be determined by the institution or provider on an individual basis before any conclusions are drawn on the relative speed or utility of this access method.
Once the IO catheter was in place, we found that a number of medications could be safely and effectively administered, including most medications needed for cardiopulmonary resuscitation (Table 3 ). The use of IO infusion for the administration of resuscitative medications is supported by other studies. [23] [24] [25] Two of our patients were within therapeutic range on Coumadin (one for atrial fibrillation and one for pulmonary embolus), and neither patient experienced significant bleeding as a result of IO catheterization, either during catheter placement and use or after catheter removal. Neither anticoagulated patient received or required a pressure dressing over the insertion site. Only a simple band-aid was used. Consequently, we believe that patients who may require infusion of tissue plasminogen activator, heparin, or other anticoagulant during the course of their ED treatment are unlikely to incur additional bleeding risks with IO catheterization.
Although the IO route is clearly effective for the infusion of resuscitative medications, we did not find it effective for the delivery of high volumes of IV fluids. This is consistent with several preclinical studies that have shown slower or, at best, equivalent rates of rapid fluid infusion between the PIV and IO routes. 20, 26 As suggested by the package insert, flow through the intraosseous catheter must be initiated by an initial flush of at least 10 mL of normal saline and maintained with use of a pressure infusion bag inflated to 300 mm Hg. Although not precisely measured, we found IV fluid flow rates to be quite variable, with a maximal infusion rate in the range of 70 mL/min to 100 mL/min with the use of pressure bag inflated to 300 mm Hg. Even with pressurized infusion, most catheters supported little more than a fast drip rate, and only a few achieved the kind of continuous stream of infusion required for high-volume resuscitation. Anecdotally, we noticed that infusion rates seemed to improve after administration of certain medications, specifically magnesium and dopamine, and that flow rates seemed to be higher in our anticoagulated patients. Further studies may be warranted to support these findings. Higher infusion pressures (Ͼ300 mm Hg) may also increase flow rates through the PHIO catheter, and Lairet and coworkers are currently investigating this hypothesis using swine animal models (Julio Lairet DO, January 30, 2009, personal communication). Although their preliminary results are promising, the results of this study have not yet been released. However, Ong et al. 27 have shown that EZ-IO catheter flow rates at the proximal humerus with a standard pressure bag are not statistically different from rates through the proximal tibia site (153.2 mL/min vs. 165.3 mL/min). These results agree with our conclusion that greater pressure is needed at the humeral site to produce the high flow rates needed for large volume crystalloid resuscitation.
Many different types of complications have previously been attributed to intraosseous catheterization in case reports, including iatrogenic bone fracture, growth plate disruption, fat embolism, hematoma formation, osteomyelitis, compartment syndrome, neurovascular injury, and tissue necrosis. 28 -34 Even death from cardiac perforation with the use of the sternal route has been reported. 35 In the present study, we did not observe any of these complications, although our study was not powered to appropriately assess for catheter safety, and we did not follow-up patients after their discharge from the hospital. However, we did encounter a number of catheter dislodgements with resultant subcutaneous infusions of fluid. In every case, extremity swelling subsided within a few hours of catheter removal without any identifiable sequelae. All of these infiltrates were identified early and none led to neurovascular compromise or significant discomfort for the patient. We believe that dislodgements represent a learning curve that can be overcome with appropriate assessment of BMI relative to intraosseous needle length, as well as to enhanced attention to arm immobilization.
It is worth noting that several cases of osteomyelitis reported in the literature have been associated with the infusion of either epinephrine or hypertonic solutions through the IO route, perhaps through medication-induced tissue necrosis. 32, 36, 37 Although we did administer epinephrine to one patient during cardiopulmonary resuscitation without complications, we did not infuse hypertonic saline through any of the IO catheters. Although hypertonic saline may seem to be a potential adjunct to IO catheter resuscitation considering the slow rates of flow we observed, we cannot recommend the infusion of hypertonic solutions through the IO route for this reason. In regards to needle length, we found that patients with a BMI of greater than 30 kg/m 2 (obese) required a needle length greater than the standard 25-mm set supplied with the adult (AD) EZ-IO system. In these patients, the flange of the shorter needle often indented the skin, leading to almost immediate catheter dislodgement as arm elevation or abduction pried the catheter loose. In our study, we adapted the Vidacare 68-mm OnControl needles, originally designed for iliac crest bone marrow aspiration, for use with our obese patients. Results of PHIO catheterization with this longer needle set were quite satisfactory and are recorded in Table 4 . Only one of the five 68-mm PHIO catheters placed in this study extravasated because of excessive manipulation of the catheter during the patient's early resuscitation efforts. However, our experiences have prompted the catheter manufacturer to develop a mid-sized 45-mm needle set for use in patients with excessive adipose or muscle tissue overlying the humeral insertion site. We believe that this longer needle may offer a better solution for PHIO access in certain patient populations. It may also be advantageous to assess the thickness of subcutaneous tissues at various potential insertion sites (i.e., proximal humerus, proximal tibia, etc.) before needle selection and insertion to potentially eliminate this dislodgement problem.
We found that extensive arm elevation or abduction can cause dislodgement of the PHIO catheter, even in very thin patients. Consequently, although we relied on patient compliance for arm immobilization in the present study, we recommend complete immobilization of the arm to prevent inadvertent dislodgement with patient activity or transfer. This can be accomplished either with a sling or by taping the arm to the side of the chest. Early in our study, we realized that patients requiring computed tomography scans of the thorax with arms extended over the head were at high risk for catheter dislodgement. Although the quality of computer tomography (CT) imaging obtained may be slightly reduced by artifact from the patient's arm tucked alongside the thorax, we recommend this modification to the usual CT protocol in PHIO patients. In all of our cases, the quality of the CT imaging obtained using this modification was adequate to evaluate for intrathoracic pathology.
The second most common complication was pain. The pain response both to initial insertion and to subsequent infusion was, as expected, highly variable. Some awake patients complained of significant pain, even with very slow rates of infusion (10 mL over 2 minutes), whereas others cited only minor discomfort at the same infusion rates. Interestingly, when hypersensitive responders were asked which hurt them more, IO placement or Foley catheter placement, they almost invariably reported that the Foley catheter insertion hurt more. Regardless, patients clearly experienced more pain with PHIO catheterization than with PIV placement, leading us to recommend PHIO catheterization only in obtunded patients. In those cases in which PHIO catheterization is the only viable venous access route, judicious use of 2% Lidocaine for local anesthesia of the medullary space may be beneficial in reducing the pain from insertion and infusion. Of course, the maximum safe dose of Lidocaine should be calculated and strictly adhered to in all cases, and only Lidocaine prepared for intravenous use should be administered. Although we used only 2 mL to 5 mL (40 -100 mg) of 2% Lidocaine in this study, higher doses may be safely used for intramedullary anesthesia in many patients.
Even in our small series, there were a number of cases in which IO access was absolutely life saving. Immediate PIV and central IV access was or would have been impossible given the circumstances of a combative or seizing patient or an IV drug abuser, renal dialysis patient, or morbidly obese patient with no identifiable peripheral veins. Table 3 provides a list of medications infused within seconds of PHIO venous access that enabled life-saving clinical interventions. Surprisingly, only one patient in the CVC group required transfusion of blood products in the resuscitation bay, although 32 of 57 (56.1%) PIV patients, three of five (60%) CVC patients, and 15 of 30 (50%) IO patients received at least one bolus of crystalloid (0.9% normal saline) before leaving the resuscitation bay. Table 5 provides a list of the presenting complaints treated with conventional intravenous access methods and those treated with PHIO catheterization. As this table demonstrates, many of the patients who received PHIO catheterization had serious life-threatening conditions that would reasonably be expected to require immediate access to the venous circulation for the administration of medications and fluids. These cases alone established the value of PHIO that will define its place in the venous access algorithm at our institution.
As these results demonstrate, PHIO catheterization may be successfully used in a wide variety of resuscitative encounters, including both medical and trauma resuscitations. Of course, limitations on the use of PHIO access may apply to specific trauma populations, including those in need of immediate large volume resuscitation, with suspected or known hu- meral fractures, and those with soft tissue compromise (e.g., burn, infection) over the proposed insertion site. Decisions regarding the type of venous access needed must always be tailored to meet the specific needs of the patient and situation. However, at the present time, we can only recommend PHIO access for those patients in which traditional IV access methods are difficult or impossible, and for whom the need for immediate access outweighs the potential for patient discomfort. That said, we believe that anticipated future advances in local anesthesia and infusion methods will undoubtedly expand the role of IO access in emergent resuscitation, benefiting both the medical and trauma resuscitation populations alike.
CONCLUSIONS
In conclusion, we found that PHIO is best used in the obtunded patient with difficult peripheral venous access and can be life saving in extreme emergencies where immediate intravenous access is needed to deliver medications. We found PHIO catheterization to be extremely useful in morbidly obese patients, IV drug abusers, and renal dialysis patients with poor peripheral veins. We also found it useful in combative or seizing patients in whom PIV or CVC placement was exceedingly difficult or dangerous to the patient or to the provider. PHIO catheterization can provide immediate access to the central venous circulation for sedative and anticonvulsant medications, glucose, and a host of other potentially life-saving medications. Future studies are needed to develop a complete venous access algorithm and practice management guidelines for the optimal use of either conventional or IO venous access relative to the need for rapid insertion, safety, and efficacy to meet the level of emergency at hand.
